Tag: biologics cdmo market insights

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Expected Growth Rate of the Biologics CDMO Market from 2024 to 2033?

The biologics CDMO market has rapidly grown, anticipated to rise from $18.44 billion in 2023 to $21.30 billion in 2024 with a CAGR of 15.4%. Growth drivers include increased biologics development, cost efficiency, a focus on core competencies, regulatory compliance, and the globalization of pharmaceutical supply chains.

The biologics CDMO market is projected to experience significant growth, reaching $36.54 billion by 2028 at a CAGR of 14.4%. This growth is attributed to the demand for biologic therapies, biosimilars, and investments in biomanufacturing. Key trends will include the expansion of capabilities and the adoption of single-use technologies.

Claim Your Free Sample of the Global Biologics CDMO Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Key Factors Are Fueling the Growth of the Biologics CDMO Market?

The rising demand for cell and genetic therapy is anticipated to drive the biologic CDMO market. These therapies utilize living cells or genetic material to treat diseases. The demand for such therapies is increasing due to their innovative approaches. Biologic CDMOs provide expertise in producing cell and gene therapies. The American Society of Gene & Cell Therapy reported a 7% growth in the therapy pipeline in 2022, reaching 3,726 therapies. Therefore, the demand for cell and genetic therapy is driving the biologic CDMO market.

What Are the Major Segments of the Biologics CDMO Market?

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

What New Trends Are Transforming the Biologics CDMO Market?

Major companies in the biologics CDMO market are advancing solutions like new cell lines to enhance biopharmaceutical development. In November 2023, Lonza Group launched GS Effex cell lines, producing antibodies that are fucose-free and demonstrate increased potency for immunotherapy applications.

Order Now for Fast Delivery of Your Biologics CDMO Market Report!

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Regions Are Driving Growth in the Biologics CDMO Market?

North America was the largest region in the biologics CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Biologics CDMO Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the biologics cdmo market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Biologics CDMO Market Include

1. Biologics CDMO Market Executive Summary

2. Biologics CDMO Market Segments

3. Biologics CDMO Market Size And Template Market Growth Rate

4. Key Biologics CDMO Market Trends

5. Major Biologics CDMO Market Drivers

……

25. Key Mergers And Acquisitions In The Biologics CDMO Market

26. Top Biologics CDMO Companies

27. Biologics CDMO Market Opportunities And Strategies

28. Biologics CDMO Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Biodegradable Plastics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biodegradable-plastics-global-market-report

Soap And Other Detergents Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/soap-and-other-detergents-global-market-report

Detergent Chemicals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/detergent-chemicals-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Biologics CDMO Global Market Report 2024, the biologics CDMO market is expected to show promising growth in the forecast period.

The biologics Contract Development and Manufacturing Organization (CDMO) market has witnessed substantial growth in recent years, driven by increasing biologics development and outsourcing trends. From $18.44 billion in 2023, the market is projected to reach $21.30 billion in 2024, growing at a CAGR of 15.4%. Looking ahead, it is expected to expand further to $36.54 billion by 2028, with a CAGR of 14.4%. This growth trajectory can be attributed to several factors:

• Biologics Development Surge: Rise in demand for biologic therapies, including biosimilars and biobetters.
• Technological Advancements: Adoption of single-use technologies and continuous manufacturing processes.
• Globalization of Supply Chains: Focus on supply chain resilience and risk mitigation.
• Regulatory Harmonization: Streamlined processes for expedited approvals.

Rise In Demand For Cell And Genetic Therapy Fuels Biologics CDMO Market Growth

The increasing demand for cell and gene therapy is a significant driver for the biologics CDMO market. These therapies represent innovative approaches in treating diseases at the genetic or cellular level, offering solutions for previously incurable conditions. Biologic CDMOs play a crucial role in supporting these therapies by providing expertise in handling living cells, viral vectors, and genetic materials. This expertise ensures safe and efficient production while navigating complex regulatory landscapes. As of January 2023, the gene, cell, and RNA therapy pipeline showed promising growth, indicating a robust demand for such innovative treatments.

View More On The Biologics CDMO Market Report 2024 – https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Advancements In Biologics CDMO
Leading companies in the biologics CDMO sector are pioneering advanced solutions to enhance biopharmaceutical development and manufacturing capabilities. For instance, Lonza Group introduced GS Effex cell lines in November 2023, designed to produce antibodies with enhanced potency by eliminating fucose, a sugar molecule. This advancement addresses challenges in immunotherapy, offering scalable and productive solutions from discovery to commercial stages.

Bora Pharmaceuticals Expands Global Footprint
In a strategic move to bolster its global presence, Bora Pharmaceuticals acquired Eden Biologics Inc.’s CDMO assets in May 2022 for $100 million. This acquisition underscores Bora’s commitment to expanding its capabilities in biologics, macromolecules, and cell and gene therapy markets, positioning itself as a key player in the evolving biologics CDMO landscape.

Market Segmentation and Regional Insights
The biologics CDMO market is segmented by cell type (mammalian, non-mammalian) and product type (biologics, biosimilars). North America led the market in 2023, driven by technological advancements and robust healthcare infrastructure. Meanwhile, Asia-Pacific is poised to witness the fastest growth during the forecast period, supported by increasing investments in biomanufacturing and favorable regulatory frameworks.

Key Players in the Biologics CDMO Market
Major companies shaping the biologics CDMO landscape include AbbVie Inc., Thermo Fisher Scientific Inc., Lonza Group Ltd., and WuXi Biologics (Cayman) Inc. These entities are pivotal in driving innovation, expanding capabilities, and meeting the rising demand for biologic therapies worldwide.

In conclusion, the biologics CDMO market is poised for substantial growth, fueled by advancements in biotechnology, rising demand for innovative therapies, and strategic expansions by key industry players. As the market continues to evolve, stakeholders must adapt to technological innovations and regulatory shifts to capitalize on emerging opportunities.

Request A Sample Of The Global Biologics CDMO Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=14056&type=smp